Patho ex1!!!!

K Diabetes Mellitus Exam 1

• Type 1 Diabetes Mellitus (T1DM):

  • Etiology and Pathogenesis: Caused by an autoimmune response involving the infiltration of T lymphocytes that directly destroy pancreatic beta cells, resulting in absolute insulin deficiency.

  • Metabolic Derangements: Absolute insulin deficiency leads to uninhibited glycogenolysis (breakdown of glycogen) and gluconeogenesis (synthesis of glucose from non-carbohydrate sources).

  • Pathogenesis of Glycosuria and Hypovolemia: When circulating blood glucose exceeds the maximum renal tubular reabsorption capacity for glucose, excess glucose spills into the urine (glycosuria). This high glucose concentration in the renal filtrate creates an osmotic gradient, drawing fluid into the tubules and leading to osmotic fluid loss, severe polyuria, and profound hypovolemia.

• Type 2 Diabetes Mellitus (T2DM):

  • Etiology and Pathogenesis: Characterized primarily by peripheral insulin resistance—a condition defined as decreased tissue sensitivity and responsiveness to insulin—alongside progressive beta-cell dysfunction.

  • Insulin Resistance Mechanics: Due to receptor and post-receptor signaling impairments, target tissues require significantly higher concentrations of insulin to perform the same biological action as in healthy cells.

  • Cellular Glucose Transport: Under normal physiological conditions, the pancreas detects elevated blood glucose levels and secretes insulin. Insulin binds to specific plasma membrane receptors, signaling specialized transporter proteins to move to the cell surface and transport glucose into the cells to meet metabolic energy needs.

• Fasting and NPO Dynamics:

  • In a fasting state or when a client is designated nothing by mouth (NPO), glucagon acts as the dominant metabolic hormone over insulin to maintain euglycemia through hepatic glycogen breakdown and gluconeogenesis.

Diagnostic Criteria & Laboratory Monitoring in Diabetes

• Glycosylated Hemoglobin (HbA1c):

  • Clinical Significance: Reflects a client's average blood glucose concentration over the preceding $90\text{--}120\,\text{days}$, which aligns with the typical lifespan of circulating red blood cells.

  • Normal Threshold: An HbA1c level of $5.5\%$ or lower is within normal physiological limits.

  • Pre-diabetes Criteria: An HbA1c level of $6.0\%$ falls directly within the pre-diabetes diagnostic range of $5.7\% - 6.4\%$.

• Fasting & Plasma Glucose Diagnostic Thresholds:

  • Normal Fasting Glucose: A baseline fasting blood glucose level is approximately $90\,\text{mg/dL}$.

  • Diagnostic Findings for Diabetes: Finding $2$ fasting blood glucose levels of $>130\,\text{mg/dL}$ measured $24\,\text{hours}$ apart indicates severe hyperglycemia and warrants comprehensive diagnostic evaluation for diabetes mellitus.

  • Oral Glucose Tolerance Testing (OGTT): A $2\text{-hour}$ plasma glucose reading of $120\,\text{mg/dL}$ following an oral glucose load represents a normal glucose tolerance response.

• Diagnostic Differentiation:

  • Valid diagnostic laboratory tests used to confirm diabetes mellitus include fasting plasma glucose, glycosylated hemoglobin (HbA1c), and $2\text{-hour}$ plasma glucose testing.

  • Triglyceride levels evaluate lipid metabolism and cardiovascular risk in metabolic syndrome, but they are not a diagnostic test for confirming diabetes mellitus.

Hormonal Regulation & Stress-Induced Hyperglycemia

• Glucagon Physiology:

  • Source: A polypeptide hormone synthesized and secreted primarily by the alpha cells of the pancreatic islets of Langerhans.

  • Physiological Actions: Glucagon acts on the liver to promote glycogenolysis (breakdown of stored glycogen) and gluconeogenesis, stimulating the release of glucose into the bloodstream when blood glucose levels drop.

  • Hormonal Regulation: Glucagon does not inhibit the release of insulin from the pancreatic beta cells.

• Stress Hyperglycemia Mechanisms:

  • Neuroendocrine Pathway: Acute physical trauma (e.g., injuries sustained in a motor vehicle crash) or severe acute infections (e.g., pneumonia) trigger the sympathetic nervous system.

  • Hormonal Mediators: Sympathetic stimulation releases neurotransmitters and stress hormones, predominantly catecholamines (alongside cortisol), which dramatically increase hepatic glucose production (glycogenolysis and gluconeogenesis) and cause acute stress hyperglycemia.

  • Clinical Management during Acute Illness: Hospitalized clients with T2DM who develop acute illnesses such as pneumonia experience catecholamine-mediated hyperglycemia. Consequently, they often require temporary administration of exogenous insulin to achieve glycemic control, even if they do not take insulin at home.

• Nervous System Integration:

  • The autonomic and central nervous systems are directly involved in regulating and influencing the biological utilization of glucose across peripheral tissues.

Special Populations: Gestational Diabetes & Neonatal Considerations

• Gestational Diabetes Mellitus (GDM) Pathophysiology:

  • Hormonal Cause: Elevated levels of placental hormones produced during pregnancy induce maternal peripheral insulin resistance.

  • Prognosis: Although GDM usually resolves after delivery, clients with a history of gestational diabetes carry a significantly higher risk of developing overt Type 2 Diabetes Mellitus later in life.

• Risk Factors for GDM:

  • Recognized Factors: Maternal obesity, direct family history of diabetes (e.g., parent or sibling), and a history of glucosuria.

  • Infant Birth Weight Significance: Delivering a normal-weight infant weighing $7\,\text{lb}$ ($3.18\,\text{kg}$) is not a risk factor for GDM. High-risk status is associated with a history of delivering a macrosomic infant weighing $>9\,\text{lb}$ ($>4000\,\text{g}$).

• Pathophysiology of Neonatal Hypoglycemia:

  • In Utero Mechanism: Uncontrolled maternal hyperglycemia leads to excessive glucose crossing the placental barrier into the fetal blood supply.

  • Fetal Pancreatic Adaptation: In response to high maternal glucose, the fetal pancreas hyper-secretes high levels of endogenous insulin.

  • Postnatal Outcome: At birth, the maternal supply of glucose is abruptly cut off, but the neonate's hyperplastic pancreatic beta cells continue to produce high levels of insulin, leading to rapid and profound neonatal hypoglycemia.

Exercise, Lifestyle, & Risk Factors for Metabolic Syndrome

• Exercise Regulation of Glucose:

  • Physiological Effect: Physical exercise increases tissue insulin sensitivity, enhancing glucose entry into skeletal muscle cells independently of elevated insulin concentrations.

  • Disease Management: Engaging in routine physical exercise slows the development and progression of chronic microvascular and macrovascular complications associated with diabetes.

• Metabolic Syndrome & Cardiovascular Risk:

  • Most Recognized Symptom: Central obesity is the most prominent and clinically recognized feature of metabolic syndrome.

  • Associated Manifestations: Includes hypertension, hyperlipidemia (elevated triglycerides and reduced high-density lipoprotein [HDL]), and peripheral insulin resistance.

  • High-Risk Demographics: Individuals of Native American ethnicity with a positive family history of diabetes (e.g., a $50\text{-year-old}$ Native American client) face elevated risk for developing metabolic syndrome.

  • Screening Triggers for PHCP Referral: A client presenting with a significantly elevated triglyceride level of $280\,\text{mg/dL}$ (normal is $<150\,\text{mg/dL}$), such as a $42\text{-year-old}$ individual who exercises infrequently ($2\,\text{days/week}$), requires formal referral to a primary health care provider (PHCP) for risk management.

Cellular Adaptation, Injury, & Mechanisms of Cell Death

• Adaptive Cellular Mechanisms:

  • Atrophy: A reversible decrease in cell size and functional capacity. It represents an adaptive effort by the cell to minimize its overall energy and nutrient consumption in response to reduced workload, ischemia, or decreased hormonal stimulation.

  • Pathologic Hypertrophy: An increase in cell or organ size in response to toxic or pathologic stressors (e.g., pathologic enlargement of the liver secondary to exposure to bodily toxins).

  • Dysplasia: Disordered cellular growth characterized by persistent injury, resulting in abnormal variations in cell size, shape, and architectural organization. Full-thickness dysplastic changes in epithelial cells (as seen in inflammatory bowel disease [IBD]) form preneoplastic lesions with high potential to progress to invasive cancer.

• Cellular Injury Pathways:

  • Sodium-Potassium Pump Malfunction: Failure of ATP-dependent sodium-potassium ($\text{Na}^+/\text{K}^+$) pumps prevents active transport of sodium out of the cell. Intracellular accumulation of sodium draws water into the cell, resulting in acute cellular swelling.

  • Hypoxic Injury: Oxygen deprivation forces cells into anaerobic glycolysis, generating elevated levels of lactic acid (lactate). Lactic acid monitoring is crucial during severe hypoxic events.

  • Viral Cellular Injury: Severe viral infections induce cellular damage primarily by triggering internal self-destruction (apoptosis or direct viral-induced lysis) within infected host cells.

• Biomarkers of Cellular Breakdown:

  • Cardiac Troponin: Myocardial cell injury disrupts plasma membrane integrity, resulting in cell breakdown and leakage of intracellular troponin into the bloodstream, confirming myocardial tissue damage.

• Apoptosis:

  • Programmed cell death designed to eliminate redundant or damaged cells without causing acute inflammation or collateral tissue damage.

  • Serves as a primary pathophysiologic driver in progressive chronic degenerative conditions, such as heart failure (HF) and dementia.

Necrosis Types & Pathophysiologic Cascades

• Coagulative Necrosis:

  • Occurs primarily in response to severe focal ischemia in solid organs such as the heart or kidneys.

  • Involves structural breakdown of plasma membranes and nuclear components while temporarily maintaining structural tissue outlines.

  • Pathophysiologic Sequence in Myocardial Infarction:

    1. Ischemic cellular injury occurs due to oxygen deprivation.

    2. The plasma membrane becomes unable to maintain its electrochemical gradient.

    3. Massive influx of extracellular calcium ($\text{Ca}^{2+}$) ions occurs along with mitochondrial dysfunction.

    4. Complete degradation of plasma membranes and nuclear structures takes place.

• Caseous Necrosis:

  • A unique form of cell death classic to tuberculous infections.

  • Dead tissue appears macroscopically as white, soft, highly fragile material resembling clumpy, cottage-like cheese.

General Disease Concepts, Terminology, & Disease Progression

• Disease Terminology:

  • Idiopathic: Refers to a disease process or condition that arises spontaneously without a known underlying cause (e.g., idiopathic essential hypertension).

  • Risk Factors: Genetic, environmental, or behavioral attributes that increase the statistical probability of an individual developing a disease. The presence of a risk factor means an individual may develop the disease, but it does not guarantee disease onset.

  • Clinical Manifestations: Includes objective physical signs observed by clinicians and subjective symptoms reported by clients. Non-specific clinical manifestations require further thorough assessment to determine the underlying diagnosis.

• Stages of Disease Progression:

  • Exacerbation: A stage in the clinical course of a chronic disease characterized by a sudden or dramatic increase in the severity of signs and symptoms.

  • Subclinical Stage: Disease presence without demonstrable, overt clinical manifestations.

  • Remission: A period during which the clinical manifestations of a chronic disease abate or disappear.

  • Convalescence: The stage of recovery and rehabilitation following an acute disease process or injury.

• Age-Related Cardiovascular Changes:

  • Decreased cardiac output in advanced age (e.g., an $85\text{-year-old}$ client) is primarily an age-related consequence of decreased stroke volume (reduced volume of blood ejected with each ventricular contraction).